Bessemer Group Inc. Has $41.98 Million Stake in DexCom, Inc. $DXCM

Bessemer Group Inc. decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 33.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 623,870 shares of the medical device company’s stock after selling 319,073 shares during the quarter. Bessemer Group Inc. owned about 0.16% of DexCom worth $41,981,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in DXCM. Vanguard Group Inc. raised its holdings in shares of DexCom by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock valued at $4,218,063,000 after purchasing an additional 866,506 shares in the last quarter. Jennison Associates LLC increased its position in DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after buying an additional 994,300 shares during the last quarter. Geode Capital Management LLC raised its holdings in DexCom by 3.4% during the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after buying an additional 358,617 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after buying an additional 3,410,858 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of DexCom in the second quarter worth about $453,279,000. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of a number of recent analyst reports. Sanford C. Bernstein reissued an “outperform” rating and issued a $86.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. Wells Fargo & Company set a $93.00 price target on DexCom and gave the company an “overweight” rating in a report on Friday, October 31st. Piper Sandler restated an “overweight” rating on shares of DexCom in a research note on Thursday. BTIG Research decreased their price objective on shares of DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a report on Friday, October 31st. Finally, Stifel Nicolaus started coverage on shares of DexCom in a report on Tuesday, October 21st. They issued a “buy” rating and a $85.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.00.

DexCom Trading Down 1.3%

Shares of DXCM stock opened at $69.89 on Friday. The firm has a market capitalization of $27.26 billion, a P/E ratio of 38.83, a price-to-earnings-growth ratio of 1.27 and a beta of 1.49. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $93.25. The firm’s fifty day simple moving average is $68.54 and its 200 day simple moving average is $70.50. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the sale, the director directly owned 27,031 shares of the company’s stock, valued at $1,569,690.17. This trade represents a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jacob Steven Leach purchased 18,200 shares of the business’s stock in a transaction on Monday, November 10th. The stock was purchased at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the acquisition, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. This represents a 5.81% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders sold 7,866 shares of company stock worth $448,177. Company insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.